Safety and Effectiveness of Regorafenib

CompletedOBSERVATIONAL
Enrollment

1,034

Participants

Timeline

Start Date

April 8, 2014

Primary Completion Date

August 19, 2017

Study Completion Date

November 10, 2017

Conditions
Neoplasms
Interventions
DRUG

Stivarga (Regorafenib, BAY73-4506)

Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib

Trial Locations (13)

Unknown

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY